Over 158 applications for generic products pending with USFDA for approval: Lupin
NEW DELHI:Drug firm Lupin remains bullish over its US business with over 158 applications for generic products pending with the US drug regulator for approval, as per the company’s annual report for 2019-20. Sharing information with company’s shareholders, Lupin MD Nilesh Gupta and CEO Vinita Gupta said the company’s US business stabilised last fiscal and … Read more